Regeneron extends BARDA agreement for additional Inmazeb supply
REGN•Regeneron expanded its BARDA agreement by $270 million to provide additional Inmazeb doses to the U.S. government through 2031 for Ebola preparedness.
1. Additional supply
Regeneron extended its agreement with BARDA to provide additional supply of Inmazeb, adding $270 million in value. The company will deliver additional doses to the U.S. government through 2031 for Ebola preparedness.
